Slideshow

Update on Psoriatic Arthritis: 3 New Things

Author(s):

Mark L. Fuerst

What's new: reliable outcome measures, overlap in treatment targets, and immune checkpoint inhibitors.

1. Holland R, Tillett W, Korendowych E, et al. Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice. Ann Rheum Dis. 2018;77:343-347. doi: 10.1136/annrheumdis-2017-2119962. Van Mens LJJ, van de Sande MGH, van Kuijk AWR, et al. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. Ann Rheum Dis. 2018;77. doi.org/10.1136/annrheumdis-2017-2119983. Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77:393-398. doi: 10.1136/annrheumdis-2017-212257.

Related Videos
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Related Content
Søren Andrea Just, MD, PhD, associate professor, University of Southern Denmark, and Odense University Hospital – Svendborg.
November 21st 2024

AI Assessments, Robotics Perform to Rheumatologist Levels in Joint Assessment

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Megan Clowse, MD, MPH, Associate Professor of Medicine, Associate Professor in Obstetrics and Gynecology, and Associate Professor in Population Health Sciences, and Chief of the Division of Rheumatology and Immunology, Duke University School of Medicine
November 19th 2024

DZP Improves Disease Activity and Reduces Corticosteroid Use in SLE

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
Hermine Brunner, MD, MDc, MBA, Director, Division of Rheumatology, and professor, Department of Pediatrics, Cincinnati Children’s
November 18th 2024

Tofacitinib Not Superior to Placebo in Systemic Juvenile Arthritis Double-Blind Trial

Victoria Johnson
Alexei Grom, MD, Research Director, Division of Rheumatology, and Professor, Department of Pediatrics, Cincinnati Children’s
November 17th 2024

Emapalumab May Improve Response Rates in MAS Treatment

Victoria Johnson
© 2024 MJH Life Sciences

All rights reserved.